Document is current
Any future updates will be listed below
-
Authors
Pongsakornkullachart, Peerada https://orcid.org/0000-0002-9161-4491
Kulsirichawaroj, Pimchanok https://orcid.org/0000-0002-9406-8481
Kongkasuwan, Ratcharin
Tovichien, Prakarn https://orcid.org/0000-0002-5000-9930
Jitwongwai, Settapong
Kanjanauthai, Supaluck
Preeprem, Nutnicha
Limpaninlachat, Sivaporn
Sermpon, Nisasri
Sanmaneechai, Oranee https://orcid.org/0000-0002-4557-0387
- License Information
-
More Information
Article History
Received: 10 June 2024
Revised: 24 March 2025
Accepted: 8 April 2025
First Online: 23 April 2025
Competing interests
: Novartis had no involvement in the design of the study, data analysis, manuscript preparation, or in providing any comments or advice. Additionally, the authors received neither any funding from Novartis as part of this Managed Access Program (MAP). OS served on Novartis’ speaker’s bureau and research grant for a prospective observational SMA cohort in Thailand. The other authors declare that they have no conflicts of interest.
: The study protocol was approved by the Siriraj Institutional Review Board (Si 405/2022), also the historical comparator data was approved by the Siriraj Institutional Review Board (Si 860/2021), and the research was conducted in accordance with the principles of the Declaration of Helsinki.
